EFIGREL EFIGREL EFIGREL EFIGREL ATCOGREL ATCOGREL PRASU PRASU PRASU PRASU PRASU PRASU PRASU PRASU BRASO BRASO BRASO BRASO EFICLOT EFICLOT SUGLET SUGLET PREZENT PREZENT PREZENT PREZENT PROFICIENT PROFICIENT PROFICIENT PROFICIENT PROFICIENT PROFICIENT PROFICIENT PROFICIENT PRISA PRISA PRISA PRISA PRASPER PRASPER PERSIVA PERSIVA PERSIVA PERSIVA FLOPLAT FLOPLAT FLOWPLAT FLOWPLAT ASCOREL ASCOREL ASCOREL ASCOREL NATUZZI NATUZZI PIVOT PIVOT PIVOT PIVOT PROVEL PROVEL PROVEL-D PROVEL-D OBSOPREL OBSOPREL OBSOPREL OBSOPREL

Dose: 5 to 10 mg
Single Dose: 7.5 (7.5)
Frequency: 24 hourly
Route: PO
Instructions: Initiate with single loading dose of 60mg oral. Consider lowering the maintenance dose to 5 mg in patients

. The Molecular Weight of Prasugrel HCl is 409.90. Its pKa is 5.1.

Prasugrel HCl is contraindicated in conditions like Bleeding,Transient ischaemic attacks.

Prasugrel HCl produces potentially life-threatening effects which include Thrombocytopenia, Bleeding, Hypersensitivity, blood in urine, blood in stool, Peripheral edema, Thrombotic thrombocytopenic purpura, Jaundice, Atrial fibrillation. which are responsible for the discontinuation of Prasugrel HCl therapy.The signs and symptoms that are produced after the acute overdosage of Prasugrel HCl include Vomiting, Blurred vision, hepatocellular atrophy, Shortness of breadth, Mydriasis, Decreased locomotor activity, Lacrimation.The symptomatic adverse reactions produced by Prasugrel HCl are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Tiredness, Nausea, Diarrhea, Dyspnea, Hypotension, Cough, Pain in upper & lower extremities, Back pain, Mild headache, Minor chest pain, Abnormal hepatic function.

Prasugrel HCl is primarily indicated in conditions like Acute coronary syndrome (without st-segment elevation), Coronary artery disease, Myocardial infarction, Myocardial infarction (non st-segment elevation), Unstable angina.

No data regarding the interactions of Prasugrel HCl was found.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

tab Store at room temperature, Between 15°C-30°C. Protect from Moisture and Heat.

It can cause significant, sometimes fatal, bleeding. Do not use in patients with active pathological bleeding or a history of transient ischemic attack or stroke. In patients greater then or equal to 75 years of age, it is generally not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk patients (diabetes or prior MI), where its effect appears to be greater and its use may be considered. Do not start Prasugrel in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue it at least 7 days prior to any surgery. Additional risk factors for bleeding include: Body weight